C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks

Graham R. Foster,Kosh Agarwal,Matthew E. Cramp,Sulleman Moreea,S Barclay,Jane Collier,Ashley Brown,S. Ryder,Andrew Ustianowski,Daniel M. Forton,R Fox,F. Gordon,William Rosenberg,David Mutimer,Jiejun Du,Christopher L. Gilbert,Janice Wahl,Eliav Barr,Barbara Haber

C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks

2016

Graham R. Foster
Kosh Agarwal
Matthew E. Cramp
Sulleman Moreea
S Barclay
Jane Collier
Ashley Brown
S. Ryder
Andrew Ustianowski
Daniel M. Forton
R Fox
F. Gordon
William Rosenberg
David Mutimer
Jiejun Du
Christopher L. Gilbert
Janice Wahl
Eliav Barr
Barbara Haber

Meeting Abstract Conference: 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Location: Boston, MA Date: NOV 11-15, 2016 Sponsor(s):Amer Assoc Study Liver Dis

Keywords:

Elbasvir
Alternative medicine
Grazoprevir
Sofosbuvir
Physical therapy
Medicine
Internal medicine
therapy naive
treatment experienced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations